Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.

Trial Details

NCT ID
NCT07593092
Phase
PHASE1
Sponsor
Xencor, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • XmAb541
  • XmAb808
Locations (sample)
  • Lake Success, New York, United States|40.77066,-73.71763
  • New York, New York, United States|40.71427,-74.00597
  • The Bronx, New York, United States|40.84985,-73.86641
  • Fort Worth, Texas, United States|32.72541,-97.32085

Key Eligibility Criteria

  • Age ≥ 18 years.
  • CLDN6+ tumor
  • Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallo…
  • Adequate Eastern Cooperative Oncology Group performance status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →